Last reviewed 2026-04-23 · How we verify

Losmapimod tablets

Rho kinase inhibitor

Rho kinase inhibitor Used for Hypertension.

At a glance

Mechanism of action

Losmapimod is a selective inhibitor of Rho kinase, which plays a role in the regulation of smooth muscle contraction and inflammation.

Approved indications

• Hypertension

Common side effects

• Headache
• Dizziness
• Nausea

Key clinical trials

• Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH) (PHASE3)
• Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) (PHASE2)
• Losmapimod Safety and Efficacy in COVID-19 (PHASE3)
• Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets (PHASE1)
• A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging (PHASE2)
• Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
• Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD). (PHASE2)
• Phase I Study of GW856553 (Losmapimod) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Losmapimod tablets CI brief — competitive landscape report
• Losmapimod tablets updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI